SALT LAKE CITY, Dec. 3, 2019 /PRNewswire/ — Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the dosing of the first participant enrolled in the REPAIR-PD study with its lead nanocatalytic therapy, CNM-Au8, for the treatment...
Biospace’s Mark Terry Clinical Trial Review Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look. Genentech, a Roche company, presented positive results from the Phase III IMbrave150...
Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth rinse composed...
First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant reduction in CCR5 expression was demonstrated on cancer-associated cells...
Cranbury, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the expansion of its Phase 2 clinical trial of CPI-613® (devimistat)...
Phase 2 DKD trial funded by JDRF to expand in Europe and New Zealand 13 patients have completed full 48-week treatment in DKD trial; no safety signals identified Phase 2 IPF trial funded by NIH; poised to initiate patient enrollment following recently received FDA and...
Email
Text